Novartis gains CHMP support in MS, Cushing syndrome

Included November roundup of EMA’s CHMP were a positive opinion for Mayzent siponimod, which Novartis hopes will become the treatment of choice for active secondary progressive multiple sclerosis.

CHMP backed an MAA for Mayzent to treat adults with active SPMS. Novartis AG (NYSE:NVS; SIX:NOVN) believes data from the Phase III EXPAND trial showing benefit on a new biomarker associated with neurodegeneration and effects on gray matter support use of the second-generation S1PR1 agonist over other drugs for the indication (see “Novartis, Merck KGaA See Opportunity in Select Pockets of MS Patients“)...